Literature DB >> 6749900

Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas.

R A Fromtling, S Shadomy, H J Shadomy, W E Dismukes.   

Abstract

Of 90 clinical isolates of Cryptococcus neoformans studied, 3 were determined to be serotype B/C. The patients from whom these B/C isolates were obtained were identified as never having lived in or visited the areas associated with B/C serotypes. This finding suggests a broader geographic distribution of this serotype group than previously believed. The glycine-cycloheximide-phenol red medium described by Salkin and Hurd (J. Clin. Microbiol. 15:169-171, 1982) was shown to be more accurate in differentiating A/D and B/D serotype pairs of C. neoformans than the creatinine-dextrose-bromthymol blue medium described by Kwon-Chung et al. (Int. J. Syst. Bacteriol. 28:616-620, 1978).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749900      PMCID: PMC272373          DOI: 10.1128/jcm.16.2.408-410.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  4 in total

1.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

2.  New medium for differentiation of Cryptococcus neoformans serotype pairs.

Authors:  I F Salkin; N J Hurd
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 5.948

3.  Epidemiologic differences among serotypes of Cryptococcus neoformans.

Authors:  J E Bennett; K J Kwon-Chung; D H Howard
Journal:  Am J Epidemiol       Date:  1977-06       Impact factor: 4.897

4.  Cryptococcus neoformans serotype groups encountered in Oklahoma.

Authors:  H G Muchmore; E N Scott; F G Felton; R A Fromtling
Journal:  Am J Epidemiol       Date:  1980-07       Impact factor: 4.897

  4 in total
  11 in total

1.  Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.

Authors:  R A Fromtling; G K Abruzzo; G S Bulmer
Journal:  Mycopathologia       Date:  1986-04       Impact factor: 2.574

2.  Isolation of highly encapsulated Cryptococcus neoformans serotype B from a patient in New York City.

Authors:  E J Bottone; P A Kirschner; I F Salkin
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

3.  Cryptococcus neoformans in bird excreta in the city zoo of Cali, Colombia.

Authors:  L D Caicedo; M I Alvarez; M Delgado; A Cárdenas
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

4.  Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations.

Authors:  R López-Martínez; J L Soto-Hernández; L Ostrosky-Zeichner; L R Castanón-Olivares; V Angeles-Morales; J Sotelo
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

5.  Cryptococcus neoformans var. gattii in Australia.

Authors:  D H Ellis
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

6.  Serotypes and mating types of clinical strains of Cryptococcus neoformans isolated in Taiwan.

Authors:  M M Hsu; J C Chang; K Yokoyama; K Nishimura; M Miyaji
Journal:  Mycopathologia       Date:  1994-02       Impact factor: 2.574

7.  Isolation of saprophytic Cryptococcus neoformans from Puerto Rico: distribution and variety.

Authors:  A Ruiz; D Vélez; R A Fromtling
Journal:  Mycopathologia       Date:  1989-06       Impact factor: 2.574

Review 8.  Current trends in the prevalence of Cryptococcus gattii in the United States and Canada.

Authors:  Ana Espinel-Ingroff; Sarah E Kidd
Journal:  Infect Drug Resist       Date:  2015-05-11       Impact factor: 4.003

9.  Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates.

Authors:  Shawn R Lockhart; Naureen Iqbal; Julie R Harris; Nina T Grossman; Emilio DeBess; Ron Wohrle; Nicola Marsden-Haug; Duc J Vugia
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

10.  Projecting global occurrence of Cryptococcus gattii.

Authors:  Deborah J Springer; Vishnu Chaturvedi
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.